Ligand Pharmaceuticals Incorporated Stock News

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P; 500 Index wa

Credit Suisse reduced Pinterest Inc (NYSE: PINS) price target from $29 to $23. Pinterest shares closed at $15.06 on Tuesday. Wells Fargo lowered the price target for American...

Ligand price target lowered to $229 from $237 at H.C. Wainwright H.C. Wainwright LGND SAGE

Alliancebernstein L.P. lessened its holdings in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 2.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission.

Ligand Pharmaceuticals (NASDAQ:LGND)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Monday, AnalystRatings.com reports. They presently have a $237.00 targe

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

The "Global Immune Checkpoint Inhibitors Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering.

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced tha

H.C. Wainwright says Captisol a 'key focus' for Ligand, reiterates Buy H.C. Wainwright LGND

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma (LGND) today and set a price target of $237.00. The company's shares

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma ( LGND – Research Report ) today and set a price target of $237.00 . The company’s shares closed last Monday at $7

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provides a general corporate update, as follows:

Mason Street Advisors LLC trimmed its position in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 6.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Com

Advisors Asset Management Inc. reduced its holdings in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 13.6% during the 4th quarter, Holdings Channel reports. The firm owned 5,448 shares of the biotechno